Regeneron's Pasatru Receives FDA Approval for Rare Bone Disease

Regeneron Pharmaceuticals has secured FDA approval for its medicine Pasatru, a treatment for an ultra-rare disease that causes bone to grow in places it shouldn’t.

The disease in question is fibrodysplasia ossificans progressiva, or FOP, a condition that affects only a handful of people worldwide. Those with FOP typically rely on wheelchairs by age 25 as the bone accumulation locks up their limbs, and only some live into their 50s.

Pasatru is the result of a three-decade-long effort to find a treatment for FOP. The hope is that the new medicine can help patients maintain their mobility and live longer.

According to Richard Keen, primary investigator in the pivotal trial for Pasatru, the medicine has shown promising results. Keen, of London’s Royal National Orthopaedic Hospital, stated that Pasatru is almost completely stopping the new bone formation, which in turn means that the condition will not deteriorate.

## FDA Approval for Pasatru

Pasatru has been granted FDA approval, marking a significant milestone in the treatment of FOP. This approval is a result of the efforts of Regeneron Pharmaceuticals and the researchers involved in the pivotal trial.

## The Impact of Pasatru

The impact of Pasatru on patients with FOP is significant. By maintaining mobility and potentially increasing life expectancy, Pasatru offers new hope to those affected by this rare condition.

The approval of Pasatru is a testament to the dedication of researchers and pharmaceutical companies working to find treatments for rare diseases. It highlights the importance of continued research and development in the field of medicine.

## The Future of FOP Treatment

The approval of Pasatru is a significant step forward in the treatment of FOP. However, more research is needed to fully understand the effects of the medicine and to identify potential new treatments.

Pasatru is not a cure for FOP, but it offers a new tool for managing the condition. As research continues, it is likely that we will see further advancements in the treatment of FOP.

| Medicine | Pasatru | | --- | --- | | Condition | Fibrodysplasia ossificans progressiva (FOP) | | Approval | FDA approval | | Effectiveness | Almost completely stops new bone formation |

Regeneron Pharmaceuticals' Pasatru has earned FDA approval for treating fibrodysplasia ossificans progressiva, a rare condition causing abnormal bone growth. The approval is a result of a three-decade-long effort to find a treatment for FOP, and it offers new hope to those affected by this rare condition.